Tag: Pfizer

Pfizer Inc. is an American global pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. It is among the world’s largest pharmaceutical companies. Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology.

EC has Approved Tafamidis for Transthyretin Amyloid Cardiomyopathy

pfizer
Pfizer Inc. announced that the European Commission (EC) has approved VYNDAQEL® (tafamidis) for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy ...

Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts

Pfizer will become the first company to bring three oncology monoclonal antibody (mAb) biosimilar treatments to the U.S. market Pfizer announced that it is introducing three new biosimilars, ZIRABEV™ ...

Biogen to Acquire Novel Clinical Stage Asset from Pfizer

biogen
Biogen Inc. Jan. 13, 2020 announced an agreement to acquire from Pfizer Inc. PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patien...

Pfizer and Theravance Biopharma Signed License Agreement on JAK Inhibitors

Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. and Pfizer Inc. announced that the companies have entered into a global license agreement for Theravance Biopharma’s pr...

Sosei Presented the First Phase I Clinical Start from Discovery Collaboration With Pfizer

pfizer
Sosei Group Corporation has been notified by its strategic alliance partner Pfizer that it has dosed the first subject in a clinical trial with a new drug candidate nominated from the multi-target dru...

FDA Granted Priority Review to Pfizer sNDA for BRAFTOVI®

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application (sNDA) for BRAFTOVI® (encorafenib) in...

FDA Approved Pfizer and Astellas Pharma XTANDI®

Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for XTANDI® (enzalutamide) for the treatment of patient...

NICE Approved Pfizer’s Ibrance for Treatment of Metastatic Breast Cancer

pfizer
The UK National Institute for Health and Care Excellence (NICE) has approved Pfizer’s Ibrance (palbociclib) for use in combination with fulvestrant for the treatment of women with hormone receptor pos...

Pfizer’s Ibrance Approved for Use by NHS in England

Pfizer’s Ibrance has been approved for use by the NHS in England as a second-line treatment for advanced breast cancer after hormonal therapy, catching up with rival drugs in the class. The decision ...

Pfizer, Novartis and 11 Drugmakers Set Aside $2bn to Invest in Gene Therapy Manufacturing

gene therapy
Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control the ...

Five Promising Drugs that Could Turn Pfizer Fortune Around

While much of the focus on Pfizer’s pipeline has been on the breast cancer drug Ibrance, there are four other new drugs worth watching that could turn the stock around. The future of the pharmaceut...

ViiV Healthcare, Pfizer and Shionogi Announced Development of Investigational Antibody N6LS

viiv healthcare
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the company will be developing the investigation...

BAVENCIO® Approved in Russia for Metastatic Merkel Carcinoma Treatment

merck kgaa
The Merck and Pfizer Alliance announced that the Ministry of Health of the Russian Federation has approved BAVENCIO® (avelumab, avelumab), as monotherapy in previously treated patients with metastatic...

FDA Approved ABRILADA™, biosimilar to Humira®

pfizer
Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab), for the treatment of certain patien...

EC Approved BAVENCIO® for Advanced Renal Cell Carcinoma Treatment

merck kgaa
Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. announced that the European Commission (EC) has approved BAVENCIO® (av...

Pfizer UK Recall Docetaxel Injection

Pfizer UK Limited is recalling batches as routine stability testing has identified that levels of a known impurity, 10-oxo-docetaxel, may exceed the acceptable level at end of shelf-life. ...